ESMO 2017 Congress

Oncology Meeting Resources

08 Sep - 12 Sep 2017, Madrid, Spain

ESMO-2017-square

The ESMO 2017 Congress, in partnership with the European Association for Cancer Research (EACR), will bring cancer researchers and clinicians together to enable collaboration and the exchange of ideas, from the laboratory to the bedside and back.
Presentations (slides) and webcasts are available to ESMO members according to the presenters' agreement to release them. Abstracts are open access. Congress attendees should access via the ESMO Conferences platform .
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programmeFuture ESMO meetings

Watch the ESMO scientific videos!

Special Sessions and Tracks





Format available

https://oncologypro.esmo.org/Meeting-Resour...ress/ESMO-Lifetime-Achievement-Award-lecture

Date: 08 Sep 2017
Presenter: José Baselga
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...O-2017-Congress/EACR-2017-Scientific-Address

Date: 08 Sep 2017
Presenter: Richard Marais
Resources: Webcast

https://oncologypro.esmo.org/Meeting-Resour...7-Congress/Presentation-of-the-ESMO-Award-by

Date: 08 Sep 2017
Presenter: Christoph Zielinski
Resources: Webcast

https://oncologypro.esmo.org/Meeting-Resour...-lecture-Oncology-The-importance-of-teamwork

Date: 08 Sep 2017
Presenter: Miguel Martin Jimenez
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...-of-the-ESMO-Translational-Research-Award-by

Date: 08 Sep 2017
Presenter: Christoph Zielinski
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...ng-and-targeting-colorectal-cancer-evolution

Date: 08 Sep 2017
Presenter: Alberto Bardelli

https://oncologypro.esmo.org/Meeting-Resour...ESMO-2017-Congress/EACR-Presidential-Address

Date: 08 Sep 2017
Presenter: Anton Berns
Resources: Webcast

https://oncologypro.esmo.org/Meeting-Resour...JC-Final-analysis-of-a-Phase-III-study-JACOB

BackgroundTargeting HER2 with H + CT significantly improves overall survival (OS) vs CT alone in patients (pts) with HER2-positive mGC/GEJC. In HER2-positive metastatic breast cancer, P + H + docetaxel...

Date: 08 Sep 2017
Presenter: Josep Tabernero
Resources: Abstract, Presentation
Topics: Anticancer Agents, Oesophageal Cancer, Gastric Cancer, Prostate Cancer, Gastrointestinal Cancers, Therapy, Biological Therapy

https://oncologypro.esmo.org/Meeting-Resour...t-Analysis-by-PD-L1-Expression-ATTRACTION-02

BackgroundNivo monotherapy demonstrated its efficacy with manageable safety for G/GEJ cancer refractory or intolerant to standard chemotherapy at the primary analysis (ATTRACTION-02[ONO-4538-12]: ASCO-GI 2017, Kang YK et al.

Date: 08 Sep 2017
Presenter: Narikazu Boku
Resources: Abstract, Presentation, Webcast
Topics: Oesophageal Cancer, Gastric Cancer, Prostate Cancer, Immunotherapy, Gastrointestinal Cancers, Therapy

https://oncologypro.esmo.org/Meeting-Resour...radiotherapy-RT-a-randomized-phase-III-trial

BackgroundHrPC pts with PSA relapse after local therapy may have a poor prognosis and AS may be a therapeutic option. D+AS is standard of care in hormone-naive metastatic PC.

Date: 08 Sep 2017
Presenter: Stephane Oudard
Resources: Abstract, Presentation, Webcast
Topics: Anticancer Agents, Prostate Cancer, Genitourinary Cancers, Surgical Oncology, Therapy, Biological Therapy, Radiation Oncology